alexa Intravitreal ranibizumab in retinal macroaneurysm.
Ophthalmology

Ophthalmology

Journal of Clinical & Experimental Ophthalmology

Author(s): Wenkstern AR, Petersen H

Abstract Share this page

Abstract PURPOSE: To present the effect of intravitreal ranibizumab (Lucentis®) therapy in a patient suffering from retinal macroaneurysm. METHODS: Case report. An 82-year-old female patient was diagnosed with retinal macroaneurysm of the inferior temporal artery with macular edema. Functional and morphological data at baseline and at 4 weeks, 3 months, and 5 months after the initiation of therapy with two intravitreal ranibizumab (Lucentis®) injections followed by focal argon laser coagulation surrounding the retinal macroaneurysm are presented. RESULTS: Best-corrected visual acuity improved from 20/50 at baseline to 20/20 at 3-month follow-up and maintained stable at 20/25 through 5-month follow-up. Central retinal thickness measured by optical coherence tomography decreased from 510 µm at baseline to 148 µm at 5-month follow-up. Fluorescein angiography demonstrated closure of the retinal macroaneurysm at 6-week follow-up. No ocular or systemic side effects were detected. CONCLUSIONS: Intravitreal ranibizumab (Lucentis®) therapy may close the retinal macroaneurysm leading to resolution of the associated macular edema and consequently visual improvement. To our knowledge, this is the first case of a retinal macroaneurysm benefiting from treatment with intravitreal ranibizumab (Lucentis®). The observed results warrant further investigation. This article was published in Graefes Arch Clin Exp Ophthalmol and referenced in Journal of Clinical & Experimental Ophthalmology

Relevant Expert PPTs

Relevant Speaker PPTs

Recommended Conferences

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

 
© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords